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Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) causes Johne’s disease in 
ruminants and is characterized by chronic gastroenteritis leading to heavy economic losses to the dairy 
industry worldwide. The currently available vaccine (inactivated bacterin in oil base) is not effective in 
preventing pathogen shedding and is rarely used to control Johne’s disease in dairy herds. To develop a 
better vaccine that can prevent the spread of Johne’s disease, we utilized polyanhydride nanoparticles 
(PAN) to encapsulate mycobacterial antigens composed of whole cell lysate (PAN-Lysate) and culture 
filtrate (PAN-Cf) of M. paratuberculosis. These nanoparticle-based vaccines (i.e., nanovaccines) were well 
tolerated in mice causing no inflammatory lesions at the site of injection. Immunological assays 
demonstrated a substantial increase in the levels of antigen-specific T cell responses post-vaccination in 
the PAN-Cf vaccinated group as indicated by high percentages of triple cytokine (IFN-γ, IL-2, TNF-α) 
producing CD8+ T cells. Following challenge, animals vaccinated with PAN-Cf continued to produce 
significant levels of double (IFN-γ, TNF-α) and single cytokine (IFN-γ) secreting CD8+ T cells compared 
with animals vaccinated with an inactivated vaccine. A significant reduction in bacterial load was 
observed in multiple organs of animals vaccinated with PAN-Cf, which is a clear indication of protection. 
Overall, the use of polyanhydride nanovaccines resulted in development of protective and sustained 
immunity against Johne’s disease, an approach that could be applied to counter other intracellular 
pathogens. 
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ARTICLE OPEN
A single dose polyanhydride-based nanovaccine against
paratuberculosis infection
Akanksha Thukral1, Kathleen Ross2,3, Chungyi Hansen1, Yashdeep Phanse1,3,4, Balaji Narasimhan2,3, Howard Steinberg1 and
Adel M. Talaat1,3,4✉
Mycobacterium avium subsp. paratuberculosis (M. paratuberculosis) causes Johne’s disease in ruminants and is characterized by
chronic gastroenteritis leading to heavy economic losses to the dairy industry worldwide. The currently available vaccine
(inactivated bacterin in oil base) is not effective in preventing pathogen shedding and is rarely used to control Johne’s disease in
dairy herds. To develop a better vaccine that can prevent the spread of Johne’s disease, we utilized polyanhydride nanoparticles
(PAN) to encapsulate mycobacterial antigens composed of whole cell lysate (PAN-Lysate) and culture filtrate (PAN-Cf) of M.
paratuberculosis. These nanoparticle-based vaccines (i.e., nanovaccines) were well tolerated in mice causing no inflammatory lesions
at the site of injection. Immunological assays demonstrated a substantial increase in the levels of antigen-specific T cell responses
post-vaccination in the PAN-Cf vaccinated group as indicated by high percentages of triple cytokine (IFN-γ, IL-2, TNF-α) producing
CD8+ T cells. Following challenge, animals vaccinated with PAN-Cf continued to produce significant levels of double (IFN-γ, TNF-α)
and single cytokine (IFN-γ) secreting CD8+ T cells compared with animals vaccinated with an inactivated vaccine. A significant
reduction in bacterial load was observed in multiple organs of animals vaccinated with PAN-Cf, which is a clear indication of
protection. Overall, the use of polyanhydride nanovaccines resulted in development of protective and sustained immunity against
Johne’s disease, an approach that could be applied to counter other intracellular pathogens.
npj Vaccines            (2020) 5:15 ; https://doi.org/10.1038/s41541-020-0164-y
INTRODUCTION
M. paratuberculosis is the causative pathogen of Johne’s disease
(JD) characterized by chronic gastroenteritis, diarrhea, weight loss
and low milk yield in ruminants.1 While JD is a worldwide problem,
its prevalence in the United States is estimated to be >90% in
dairy herds,2 causing a combined loss of $200–250 million to the
US dairy industry.3,4 The financial losses are incurred due to
premature culling of infected animals, decreased milk production,
and increased somatic cell infiltration in milk.5,6 JD is a slowly
progressing disease and can infect 38–40% of the herd before
becoming symptomatic in a single animal.7,8 Currently there is no
treatment for JD and controlling the disease progression by
culling the infected animals is very expensive, whereas vaccination
offers a reasonable alternative.9 Mycopar® (Boehringer Ingelheim)
is an oil suspended, heat killed, whole cell vaccine licensed in the
United States. However, Mycopar® fails to completely protect
against JD10,11 and can cause severe inflammatory lesions at the
site of injection.12 It also poses a health risk to vaccinators due to
accidental inoculation, which leads to a chronic inflammatory
reaction that potentially requires surgical intervention.13 Given the
challenges to control JD with the current vaccine, we directed our
efforts to develop a more effective and safe vaccine against JD
using polyanhydride nanoparticles (PAN).
An ideal vaccine should elicit a robust immune response
without causing untoward reactions in the vaccinee or risk to the
vaccinator. Another important aspect of vaccine development
against Mycobacterial infection is its capability to elicit a
polyfunctional T cell response with simultaneous production of
pro-inflammatory cytokines by T cells.14,15 To elicit robust
immunity, antigens are often formulated with adjuvants to
prolong their release and enhance their protective immunity. In
this study, we used whole cell lysate and culture filtrate proteins
encapsulated in biodegradable polyanhydride nanoparticles
(adjuvant) that provide sustained release of M. paratuberculosis
antigens by surface erosion.16 PAN-based vaccines (i.e., nanovac-
cines) have been shown to impart long lasting protective
immunity against several infectious diseases including influenza,
pneumonic plague, respiratory syncytial virus, and pneumonia,
using pathogen-specific protein antigens.16–22
The amphiphilicity of the PAN chemistry provides antigen
stability and the copolymer composition enables sustained release
of the encapsulated immunogens.21,23–27 The small size (~200 nm)
and large surface area of the nanoparticles allows them to carry
antigens across cellular membranes and deliver them to their
targets.28–30 In addition, their molecular chemistry and size has
pathogen-mimicking characteristics, allowing PAN to be engulfed
by, persist within, and subsequently stimulate antigen presenting
cells (APCs).31,32 Polyanhydride particles on their own exhibit
adjuvant-like properties by activating APCs31–33 and inducing both
humoral and cell-mediated immune responses;17,33–35 formulating
them with immune-stimulatory antigens results in protective
immunity.22,35 Finally, these particles have been shown to be safe
and induce less inflammation at the administration site compared
with traditional adjuvants such as Alum and incomplete Freund’s
adjuvant.36,37
M. paratuberculosis whole cell lysate and culture filtrate proteins
have been shown to exhibit immunogenic properties and have
previously been evaluated as a potential vaccine.38,39 Therefore,
we utilized M. paratuberculosis antigens together with PAN to
formulate nanovaccines that can elicit robust and sustainable
protective immune responses. In this study, a single, subcuta-
neous dose of nanovaccine in C57BL/6 mice was evaluated for
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protection against M. paratuberculosis JTC-1285 challenge in
comparison to both inactivated and live vaccine candidates. The
live vaccine candidate lipN, developed previously by our group,
was constructed by knockout of a fatty acid lipase/esterase gene
lipN from M. paratuberculosis K10. This gene was significantly
upregulated in M. paratuberculosis shed in the cow feces, as
revealed by transcriptional profiling.40 Also, lipN mutant was
analyzed and found to be attenuated in mice as indicated by
reduced histopathological lesions and colonization of the liver.41
Its protective efficacy has been observed in goats challenged by
virulent M. paratuberculosis strain.42 The study was conducted in
two phases, viz: Trial I and Trial II. In the trial I studies, the focus
was on the safety of the nanovaccine formulations while in the
trial II studies, the focus was on the efficacy of nanovaccine
formulations (Fig. 1).
RESULTS
Nanovaccine characterization and safety
Scanning electron photomicrographs of M. paratuberculosis lysate-
encapsulated (PAN-Lysate) and culture-filtrate (PAN-Cf)-encapsu-
lated polyanhydride nanoparticles showed similar spherical
morphology and size as blank (i.e., empty) nanoparticles,
indicating that antigen encapsulation did not change the average
diameter, which was ca. 200 nm (Fig. 2). The encapsulation
efficiency of the lysate into the nanoparticles was 40.0 ± 1.9% and
that of the culture filtrate was 26.0 ± 0.4% and 2.5 wt% of the
protein content of the lysate or culture filtrate (Cf) was
encapsulated into the particles. To evaluate nanovaccine safety,
we monitored immunized mice on a daily basis. Animals
vaccinated with Mycopar® gradually developed an abscess at
the injection site which progressed and persisted throughout the
study (Supplemental Fig. 7). On the other hand, no lesions were
observed in nanovaccine-immunized and live attenuated (lipN)
vaccine immunized animals. At 6 weeks post-vaccination (WPV)
and before any challenge, histopathology of vaccinated mice
groups demonstrated lymphoid depletion in the spleens of
animals immunized with the commercial vaccine, while minimal
to moderate lymphocytic infiltration and granulomatous inflam-
mation was observed in the livers of the rest of vaccinated animals
regardless of formulation, which is indicative of induced immunity.
No pathology was observed in the negative control group (PBS-
vaccinated mice).
Pre-challenge immune responses
For Trial I (i.e., safety study), the T cell response was evaluated at
6 weeks post-vaccination by performing IFN-γ ELISA on spleen
derived lymphocytes (described in Methods) (Supplemental Fig.
1). The Mycopar-vaccinated animals showed significantly higher
IFN-γ levels than the rest of the groups (***p < 0.001) (Supple-
mental Fig. 2a). For Trial II (i.e., efficacy study), spleen derived
lymphocytes were stained with various antibody markers and
analyzed using flow cytometry. We assessed antigen specific,
polyfunctional T cell responses by multi-parametric flow-cytome-
try. In this analysis, LipN vaccinated mice showed significantly
higher percentage of double cytokine (IFN-γ,TNF-α) and single
cytokine (IFN-γ) producing CD4+ T cells as well CD8+ T cells in
comparison with both PBS and Mycopar® vaccinated animals (Fig.
3a, b). Interestingly, the percentage of triple cytokine producing
(IFN-γ, IL-2, TNF-α) CD8+ T cells was significantly higher in mice
immunized with PAN-Cf when compared with PBS and Mycopar®.
Also, the PAN-Cf vaccinated animals exhibited significantly higher
double (IFN-γ, IL-2) cytokine secreting CD8+ T cells in comparison
with PBS vaccinated mice (Fig. 3b). Of note was the breadth of the
polyfunctional CD8+ T cell response observed from mice
immunized with PAN-Cf. In contrast to all the other treatment
groups where the majority of the CD8+ T cells was dominated by
IFN-γ secreting single positive cells, PAN-Cf vaccinated mice
showed a broader profile of triple, double and single cytokine
secreting CD8+ T cells (Fig. 3b).
Post-challenge immune responses
To evaluate T cell response in Trial I/safety study IFN-γ ELISA was
performed and result of which depicted no significant differences
in IFN-γ levels among the groups (Supplemental Fig. 2b) while at
12 weeks post challenge Mycopar and PAN-lysate vaccinated
animals showed significantly higher IFN-γ levels as compared with
control animals given PBS (Supplemental Fig. 2c). T cell responses
for the Trial II/Vaccine efficacy study were evaluated by flow
cytometry for which spleens from vaccinated mice were collected
at 12 and 18 weeks post-challenge (WPC). At 12 WPC, multi-
parametric flow cytometry analysis indicated that mice immunized
with PAN-Cf elicited a significantly higher percent of antigen
specific double cytokine (IFN-γ, TNF-α+) and single cytokine (IFN-γ)
producing CD8+ T cells compared with non-vaccinated and
Mycopar® vaccinated mice (Fig. 4). In addition, PAN-Cf and
Mycopar®-vaccinated animals also displayed low levels of triple
cytokine secreting CD8+ T cells. Similar to the pre-challenge CD8+
T immune response, mice immunized with PAN-Cf showed a
Fig. 1 Experimental design for vaccination and challenge. Five- to
eight-week-old female C57BL/6 mice were vaccinated with sub-
cutaneous injection and challenged six weeks later with virulent
strain of M. paratuberculosis JTC-1285 by the intraperitoneal route.
Mice (n= 5/group) were sacrificed at various time points. Tissues
and blood samples were collected to measure bacterial burden,
cytokine levels and histopathology.
Fig. 2 Characterization of M. paratuberculosis antigen-containing nanoparticle-based vaccines. Scanning electron microscopy images of
20:80 CPTEG:CPH nanoparticles loaded with 2.5% whole cell lysate (a) and 2.5% culture filtrate (b) showed similar spherical morphology and
size (~200 nm) as blank nanoparticles (c). Scale bar= 1 μm.
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Fig. 3 Pre-challenge immune response specific to lysate of M. paratuberculosis. C57BL/6 mice (n= 5) were immunized with various vaccine
groups and 6 WPV, five mice from each group were euthanized. Spleens were harvested; lymphocytes were isolated and stimulated with the
M. paratuberculosis lysate for 24 h. Cells were then stained for CD4+ (a) and CD8+ (b) cell surface markers and intracellular cytokines. The total
percentage of T cells secreting particular cytokines are indicated below each pie chart (denoted by T= number). The error bars show the
standard error of the mean for five individually analyzed mice. * indicates p < 0.05; ** indicates p < 0.001. * denotes comparison with PBS while
# denotes comparison with Mycopar®. Results were expressed as the increase in the percentage of the cells with positive staining relative to
that of an unstimulated sample stained with the same antibody.
A. Thukral et al.
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Fig. 4 Early cellular responses in vaccine groups following challenge with a wild type strain of M. paratuberculosis. Six to eight week-old
C57BL/6 mice were immunized with various vaccine candidates. At 6 WPV they were challenged with M. paratuberculosis JTC-1285 and
euthanized 12 weeks later (12 WPC). The lymphocytes were isolated from the spleens and stimulated with whole cell lysate of M.
paratuberculosis for 24 h. Cells were then stained for CD4+ (a) and CD8+ (b) cell surface markers and intracellular cytokines and were measured
by flow cytometry. The total percentage of T cells secreting particular cytokines are indicated below each pie chart (denoted by T= number).
The error bars show the standard error of the mean for five individually analyzed mice. * indicates p < 0.05; ** indicates p < 0.001. * denotes
comparison with PBS while # denotes comparison with Mycopar®. Results were expressed as the increase in the percentage of the cells with
positive staining relative to that of an unstimulated sample stained with the same antibody.
A. Thukral et al.
4
npj Vaccines (2020)    15 Published in partnership with the Sealy Center for Vaccine Development
broader profile of cytokine secreting cells at 12 WPC (see pie chart
in Fig. 3). The cumulative percentage of CD8+ T cells that were
either triple, double or single cytokine secretors was also higher in
animals vaccinated with PAN-Cf (total percentage of cells
secreting cytokine; T= 6.23) in contrast to that in animals
vaccinated with the other formulations, indicating the robustness
of the induced CD8+ T cell response. Also, animals receiving PAN-
Cf+ Lysate showed significantly higher levels of double cytokine
secreting (IFN-γ, IL-2) CD8+ T cells in comparison with animals that
received PBS and significantly higher levels of double cytokine
secreting (IFN-γ, IL-2) CD4+ T cells in comparison with animals
receiving both PBS and Mycopar®. At 18 WPC, the percentages of
mycobacterial antigen-specific double positive CD8+ T and CD4+
T cells (IFN-γ+IL-2+) were significantly higher in PAN-Cf vaccinated
mice compared with PBS-vaccinated mice (Supplemental Fig. 3).
Protection against challenge with virulent strains of M.
paratuberculosis
In spite of the fact that safety was the main goal of the Trial I
studies, we were able to evaluate the protective efficacy of each
vaccine candidate at 6WPC when bacterial colonization remained
similar in organs of all vaccinated groups (Supplemental Fig. 4). At
12WPC, the bacterial load was significantly lower in the spleens
and mesenteric lymph nodes of Mycopar and PAN-Lysate and
Lysate vaccinated groups in comparison with non-vaccinated
group. Livers of Mycopar and PAN-Lysate vaccine group showed
significant reduction in comparison with PBS group (Supplemental
Fig. 5).
To better evaluate protection offered by each vaccine formula-
tion in Trial II/Efficacy study against recent isolates of M.
paratuberculosis, we quantified the level of bacterial tissue
colonization following a challenge with M. paratuberculosis
JTC1285, a clinical isolate of the bovine origin.43 As expected,
mice that received PBS had high levels of bacterial load in all the
tissues studied (liver, spleen, intestine and mesenteric lymph
node) at 12 WPC (Fig. 5). All the vaccinated mice showed
significantly lower bacterial burden in the liver in comparison with
PBS-treated mice (Fig. 5a). Bacterial load was significantly lower in
the spleens of all vaccine groups (including Mycopar®, lipN, and
PAN-Lysate) with a two-log reduction observed in the spleens of
animals vaccinated with PAN-Cf in comparison with the load in
the spleens of animals that received PBS. The PAN-Cf immunized
mice also showed significant reduction in bacterial load burden
compared with Mycopar® vaccinated mice (Fig. 5b). Interestingly,
Mycopar® did not provide any protection in terms of a reduced
bacterial load in the small intestine (Fig. 5c) compared with the
PBS-treated animals. In contrast, mice vaccinated with lipN
mutant, PAN-Cf+ Lysate and PAN-Cf had significantly lower
mycobacterial colonization levels in the small intestine. All mouse
groups displayed a reduction in bacterial colonization of the
mesenteric lymph nodes compared with the PBS control (Fig. 5c,
d). At 18 WPC, no significant differences were observed in the
bacterial colonization in the mouse tissues among any of the
vaccine groups, including PBS (Supplemental Fig. 6).
Histopathology
To analyze the level of tissue damage induced by challenge with
the wild type M. paratuberculosis JTC1285 strain, we performed
histopathology of the main body organs in all vaccine groups. At
12 WPC, all animals administered PBS had granulomatous
inflammation in the liver while only 40% of the animals receiving
the PAN-Lysate, PAN-Cf+ Lysate, or lipN vaccine exhibited
minimal to mild pathology (Table 1; Fig. 6). The granulomatous
lesions in livers involved variable size aggregates of lymphocytes
Fig. 5 Protection against challenge strain of M. paratuberculosis. Levels of M. paratuberculosis colonization in body organs of mice at 12
WPC. The total colony counts for each individual animal for each vaccine groups are shown in spleen (a), liver (b), small intestine (c) and
mesenteric lymph node (d). Error bars indicate standard deviation. * indicates p < 0.05; ** indicates p < 0.001. * denotes comparison with PBS
while # denotes comparison with Mycopar®.
A. Thukral et al.
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with macrophages visible in some lesions. In the Mycopar®
vaccinated group, 60% of the animals had minimal to moderate
granulomatous inflammation in the liver (Table 1). At 18 WPC,
granulomatous and lymphocytic inflammation were larger in size
and involved more sections of the liver in all groups with no
significant differences among vaccine groups.
DISCUSSION
Despite many challenges and shortcomings, vaccination against
MAP is still considered to be the most efective strategy to curb
Johne’s disease.44 The commercially available vaccines, such as
Mycopar®, Gudair®, and Silirum®, are comprised of whole
inactivated MAP and provide moderate protection at best.45,46
The limited benefits provided by these vaccines are over-
shadowed by their drawbacks, which include granulomatous
Fig. 6 Histopathology of vaccinated and challenged mice. Liver tissues from PBS (a), Mycopar® (b), lipN (c), PAN-Lysate (d), PAN-Cf+ Lysate
(e), PAN-Cf (f) vaccinated mice were harvested at 12 WPC. Tissues were sectioned to 5 µm slices and stained with H&E and analyzed at 20×
magnification. Scale bar: 100 µm.
Table 1. Histopathology scores of liver at 12 WPC.
Granulomatous inflammation (GI) in liver
Vaccine groups Severity scorea % of animals with GI
PBS 2 3 1 1 1 100
Mycopar® 2 N N 3 1 60
PAN-Lysate 2 N N 1 N 40
PAN-Cf+ Lysate 2 N N 1 N 40
PAN-Cf 1 1 1 1 N 80
lipN 1 N N 2 N 40
aSeverity index of granulomatous lesions for individual animals, as follows:
N= normal, 1=minimal, 2=mild, 3=moderate, 4= severe, 5=massive.
A. Thukral et al.
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reaction at the injection site and poor protection against bacterial
tissue colonization and shedding.46,47 In this report, we utilized the
polyanhydride nanovaccine platform technology to design a safer
and more efficacious vaccine aginst JD. Previous studies have
shown that PANs can encapuslate a diverse array of biologics
including subunit proteins, peptides, and antibiotics.17,35 Here we
demonstrate that polyanhydride nanoparticles can encapsulate
complex payloads such as M. paratuberculosis proteins (from
whole cell lysates and culture filtrate) and induce effective
immune responses in mice indicating that the immunogenicity
of the encapsulated cargo is intact. This novel delivery approach
to inactivated vaccine improve their efficacy but maintain their
safety profile. The strategy of using M. paratuberculosis proteins in
both encapsulated and soluble form enables primed (provided by
the soluble protein) and sustained (provided by the nanoparticle-
encapsulated protein) immune responses.16,33,48 Consistent with
previous studies that examined the safety of inactivated vaccines
(e.g., Mycopar®),47,49 we observed abscess-like lesions at the
inoculation site in several mice vaccinated with Mycopar®
(Supplemental Fig. 7). In contrast, no adverse injection site
reactions were observed in PAN-vaccinated mice, clearly indicat-
ing their excellent safety profile. These results add to the body of
literature on the minimal reacotogenicity of polyahydride
nanovaccines, as demonstrated previously.36,50
Although oral infection and mucosal immunizations against M.
paratuberculosis could be more benificial in the target host
(cattle),51 we selected parental infection and subcutaenous
injection of mice to test vaccine formulas using an entery level
model for vaccine testing against paratuberculosis.52 For both the
murine and bovine models of paratuberculosis, CD4+ and CD8+
effector T cells play a crucial role in eliciting protective cell
mediated immunity against mycobacterial infection.53,54 Effector
T cells producing multiple pro-inflammatory cytokines such as IFN-
γ,55 TNF-α,56 and IL-257 have been shown to be associated with
protection against various intracellular pathogens including M.
tuberculosis.14,15 Even though the exact mechanism(s) of poly-
functional T cell mediated protection are still not clear, it has been
shown that two or more cytokines can work synergistically to
control infection, as in the case of a closely related mycobacter-
ium, M. tuberculosis58 and Leishmania spp.59 Indeed, PAN-Cf
vaccinated (prechallenged) mice exhibited polyfunctional CD8+
T cells (IFN-γ+, IL-2+, TNFα+) but showed superior protection
(significantly lower bacterial burden) compared with both non-
vaccinated (all organs) and Mycopar (only spleen) vaccinated
groups. We hypothesize that protection can be attributed to a
robust polyfunctional CD8+ T cell response, especially for the
nanovaccine formulas. Recently, nano-peptide based adjuvant
enhanced BCG primed immune response by induction of a robust
polyfunctional CD8+ T cells.60 Overall, the presented analyses (Figs
3, 4) clearly indicated robust induction of polyfunctional T cell
responses in mice immunized by the nanovaccines as depicted by
higher triple and double cytokine producing CD8+ T cells when
compared with non-vaccinated (PBS) and Mycopar®-vaccinated
mice. It is noteworthy to mention here that for M. tuberculosis
vaccines, polyfunctional T cells were mainly CD4+ unlike the
predominantly CD8+ population observed in animals vaccinated
with the PAN-Cf group. This is likely induced by the inclusion of
polyanhydride nanoparticles in the PAN-Cf group, consistent with
previous observations.61,62
The nanoparticle chemistry used in this study (i.e., 20:80 CPTEG:
CPH) was rationally selected based on previous reports showing
its potency as an adjuvant as exhibited by robust induction of
cellular immune responses.35 Similarly, in this study PAN-Cf
vaccinated mice at pre-challenge not only induced a polyfunc-
tional CD8+ T cell response but also had more breadth as
indicated by induction of more types of cytokine secreting cells.
The robust polyfunctional T cell response observed in PAN-Cf
vaccinated animals for 12 WPC may be attributed to sustained
release of antigen from polyanhydride particles.29 Remarkably,
PAN-Cf+ Lysate was able to produce double cytokine (IFN-γ+IL-2+)
CD4+ T cells significantly higher than PBS and Mycopar® and
exhibited lower bacterial burden in all the mice tissues as
compared with non-vaccinated mice (Fig. 6). Most importantly,
PAN-Cf vaccinated mice had the lowest bacterial burden in three
out of the four tissues evaluated. Moreover, despite this significant
reduction was not maintained at 18 WPC, the level of polyfunc-
tional T cells remained robust at this prolonged time. This
indicates that several other paramters (beyond the scope of
present study), such as Th-17 induction, tissue homing properties
of T cells, memory and effector phenotype could also play critical
roles.63,64 These parameters deserve more attention, especially as
we advance vaccine testing to ruminant models.
As expected, histological lesions post-challenge correlated with
protection based on bacterial burden in body organs. For
example, granulomatous lesions that are typical of mycobacterial
infection were seen in the liver of PBS and Mycopar®-vaccinated
animals in higher frequency than in the lipN or PAN-vaccinated
animals (Table 1), consistent with the levels of mycobacterial
colonization. Similar to other vaccine candidates (lipN mutant),
PAN-based vaccines were able to significantly lower M. para-
tuberculosis levels in the liver, spleen and lymph nodes but did not
prevent dissemination of infection. Approaches focused on
developing significant mucosal immunity at the main site of M.
paratuberculosis entry (intestine) could definitely reduce organ
dissemination of the infection. Overall, the nanovaccines and lipN
mutant were able to impart superior protective imunity against M.
paratuberculosis challenge in mice compared with a commercial
vaccine, Mycopar®. Further, in contrast to Mycopar®, nanovaccines
were also well tolerated and did not induce any adverse reactions
at the site of injection. Both these features makes PAN
nanovaccines ideal for further testing in larger animals such as
goats and cattle following mucosal immunization and oral
infections, to memic natural infection. Although promising,
nanovaccines have room for improvement before becoming
suitable for field applications. For example, methods to improve
the encapsulation efficiency of complex protein mixtures like
whole cell lysate into PAN are highly desirable and if developed,
could improve vaccine production and facilitate immunization.
Such strategies could open the door for the development of more
effective vaccines targeting other intracellular pathogens such as
M. tuberculosis.
METHODS
Bacterial strains and growth conditions
For safety experiments, M. paratuberculosis -K10 was used to prepare lysate
while for efficacy experiments, M. paratuberculosis strain JTC-1285 was
used to derive lysate and culture-filtrate (Cf) proteins for vaccine
formulation. Both isolates belong to C-type of M. paratuberculosis with
almost identical genomes.43 The same strains were used for the animal
challenge studies, as described below. The strains were grown in
Middlebrooks 7H9 broth (Difco, Sparks, MD) supplemented with 0.5%
glycerol (v/v) and 10% (v/v) ADC (albumin, dextrose, catalase) or Tween 80
and 1mg/mL mycobactin J (Allied Monitor, Fayette, MO) in a shaking
incubator at 37 °C until it reached the log phase (OD600= 0.5–1.0).
43 The M.
paratuberculosis field isolate, JTC-1285, was sub-cultured in Watson Reid
medium,65,66 modified by supplementing 1mg/mL mycobactin J (Allied
Monitor, Fayette, MO). The Watson Reid medium enabled culture filtrate
proteins to be analyzed free of bovine serum albumin (BSA) contamination.
The live attenuated vaccine strain, M. paratuberculosis ΔlipN mutant (lipN
mutant) was constructed by an in-frame deletion of 1.1 kb of the lipN gene
from M. avium subsp. paratuberculosis strain K-10 and grown in
Middlebrooks 7H9 broth in presence of 30 μg/mL hygromycin.40 This
vaccine construct was used as a control to evaluate nanovaccine
performance.
A. Thukral et al.
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Preparation of culture filtrate and lysate protein
M. paratuberculosis K10 and JTC-1285 cultures were centrifuged in pre-
weighed 50mL conical tubes at 3200 × g for 15min at room temperature.
The supernatant was filter sterilized with 0.22 μm polyethersulfone (PES)
filter (Nalgene). Further, it was size fractionated by ultrafiltration (Corning
Ultra spin columns, 5000 MWCO) and the filtered volume retained on the
membrane was dialyzed twice against 10 mM phosphate buffered saline
(PBS) (pH 7.2). The concentrated culture filtrate proteins were quantified
using bicinchoninic acid kit (Pierce) and stored at −20 °C. To obtain the
lysate, the bacterial cell pellet was resuspended in protein lysis buffer
(100mM Tris–Cl, 100 mM NaCl, 5 mM MgCl2, 1 mM PMSF, complete ultra
protease inhibitor cocktail, pH 7.5) and placed in microcentrifuge tubes
containing 0.1-mm zirconia/glass beads. Tubes were shaken in the Mini
Bead-beater cell disrupter for four 45 s pulses followed by 1-min
incubation on ice. Cellular debris and beads were pelleted by centrifuga-
tion at 3200 × g for 20 min. The supernatant was quantified for protein
using bicinchoninic acid kit (Thermo Fisher Scientific, Rockford, IL) and
stored at −20 °C.
Nanoparticle formulation and protein encapsulation
Diacids of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis
(p-carboxyphenoxy)hexane (CPH) were synthesized as described in
detail.67,68 Next, melt polycondensation was used to synthesize 20:80
CPTEG:CPH copolymer. The purity and molecular weight of the copolymer
were verified using 1H nuclear magnetic resonance spectroscopy (VXR
300MHz, Varian, Palo Alto, CA) before proceeding to nanoparticle
synthesis. Nanoparticles were synthesized using solid-oil-oil double
emulsion nanoprecipitation.31 Briefly, M. paratuberculosis lysate and culture
filtrate proteins were dialyzed to nanopure water by using 5k MWCO Spin-
X® UF Concentrators (Corning, Corning, NY) and lyophilized overnight. The
20:80 CPTEG:CPH polymer (20 mg/mL) containing 2.5 wt% proteins was
dissolved in methylene chloride. The solution was sonicated for 30 s to
ensure uniform distribution of the protein throughout the solution.
Particles were precipitated by pouring the solution into chilled pentane
(1:250 methylene chloride:pentane) and collected via vacuum filtration.
Nanoparticle size and morphology were characterized via scanning
electron microscopy (FEI Quanta 250, FEI, Hillsboro, OR). The encapsulation
efficiency was determined by incubating the nanoparticles in PBS at 37 °C.
The released protein was quantified via a micro-bicinchoninic assay
(Pierce) and compared with the amount of protein theoretically
encapsulated. The final nanovaccine formulation was a combination of
free protein and nanoparticle-encapsulated protein. A total of 1 mg of
nanoparticles encapsulating 25 µg protein was suspended in 100 μL PBS
containing 75 µg free protein per mouse. The mixture was sonicated for
30 s on ice to disperse any nanoparticle aggregates prior to administration.
Mice vaccination and challenge
Female C57BL/6 mice (5–8 weeks of age) were obtained from Taconic Inc.
and maintained in bio-safety level-2 containment. All procedures were in
compliance with Institutional Animal Care and Use Committee, University
of Wisconsin, Madison. Experiments were run in two trials (Table 2, n= 15/
group) with trials I and II comprising of four and six vaccine groups,
respectively. Animals were vaccinated subcutaneously as per the experi-
mental design shown in Table 2. In all experiments, five mice from each
group were sacrificed at 6 weeks post-vaccination. The remaining 10
animals in each group were challenged with 108 CFU of M. paratuberculosis
JTC-1285 in 100 μL of PBS, injected intraperitoneally (IP). The subcutaneous
vaccination regime and intraperitoneal challenge model has been
successfully employed before in mouse models and the resulting data
translated well to ruminant systems such as in goats.42,69,70 The dose was
confirmed by plating the serially diluted challenge inoculums on 7H10
plates. Mice were monitored daily for adverse reaction(s) from vaccination
and for the progression of infection. At 6 weeks (Trial I), 12 weeks (Trials I
and II) and 18 weeks (Trial II) post-challenge, mice (n= 5) were sacrificed
and the liver, spleen, small intestine and mesenteric lymph nodes were
harvested from each sacrificed mouse in order to quantify the bacterial
burden. Organs were homogenized in 1mL PBS and undiluted and 10-fold
serial diluted samples were plated onto antibiotic free and selective media
(hygromycin 30 μg/mL) to differentiate between lipN and challenge strain.
When the selective media were not used, organs were plated onto
standard 7H10 plates supplemented with ADC, mycobactin-J, and
vancomycin (5 mg/mL), amphotericin B (30mg/mL), and nalidixic acid
(10mg/mL) to reduce bacterial and fungal contamination. Finally, tissue
sections were collected for histopathology and stained with hematoxylin
and eosin.41 Slides were scored by a trained pathologist blinded to the
samples. The animal experimental design is shown in Fig. 1.
Splenocyte isolation and stimulation
Spleens from five animals/group were aseptically harvested and placed in
RPMI (Corning, Manassas, VA) supplemented with 1% FBS (Atlanta
biological, Lawrenceville, GA), 1% L-glutamine (Gibco, Grand Island, NY),
1% penicillin-streptomycin (Mediatech, Inc. Manassas, VA) and 1%
nonessential amino acids (Gibco). Spleens were pressed against the wire
mesh screens to isolate splenocytes. The cells were washed with RPMI and
resuspended in 1–2mL of RBC lysis buffer (Tris buffered ammonium
chloride) for 1 min, washed, and resuspended in RPMI with 10% FBS. Cells
were counted using trypan blue dye to assess viability. A total of 106 cells/
well were seeded into 96-well round bottom plates and stimulated with
10 µg/mL of whole cell lysate of M. paratuberculosis K10 (Trial I) or M.
paratuberculosis JTC-1285 (Trial II) and 100 U/mL IL-2 (BD Biosciences, San
Jose, CA). A control of unstimulated cells from each sample was also plated
and treated with 100 μL of media and 100 U/mL IL-2. Plates were
incubated for 18 h at 37 °C, 5% CO2 followed by addition of Golgi-Plug
to each well and incubated for an additional 5 h. Cells were harvested by
centrifugation and stained with immune markers to be analyzed by flow
cytometry and the supernatant was used to detect IFN-γ by ELISA.
IFN-γ ELISA
Supernatant from the stimulated splenocytes was collected and tested for
IFN-γ levels using Mouse IFN-γ ELISA MAXTM Deluxe kit (Biolegend, San
Diego, CA) following the manufacturer’s instructions. In brief, 96-well plates
(Maxisorp-Immuno plates; Nunc) were coated overnight with capture
antibody (monoclonal capture antibody specific for mouse IFN-γ) at 1:200
dilutions in the coating buffer at 4 °C. Plates were washed with PBST
(137mM NaCl, 2.7 mM KCl, 10.15 mM Na2HPO4, 1.76mM KH2PO4, pH 7.4,
0.05% (v/v) Tween 20), blocked with 200 μL of assay diluent, and incubated
on a shaking plate for 1 h at room temperature. Plates were washed five
times with the PBST and 100 μL of sample and standards were added to
the appropriate wells and incubated for 2 h on the shaking plate. Plates
were washed with PBST and 100 μL of detection antibody (biotinylated rat
monoclonal anti-mouse antibody) was added and incubated for 1 h at
room temperature. After three more washes, 100 μL of Avidin-horse radish
peroxidase conjugated solution was added to each well and incubated for
30min on the shaking incubator. After a last few washes, 100 μL of freshly
made 3’, 3, 5, 5’ -tetramethylbenzidine (TMB) substrate solution was added
to the wells and incubated for 20min in the dark. The reaction was
stopped by adding 100 μL of stop solution (1 N H2SO4). The plates were
read at a wavelength of 450 nm and analyzed with SoftMax Pro software
(Molecular Devices, Sunnyvale, CA).
Flow cytometry
Splenocytes from five individual mice per group were counted and 1 × 106
cells/well were plated in 96-well plates. Stimulated cells were harvested by
centrifuging at 400 × g for 10 min at 4 °C. Supernatants were removed and
Table 2. Vaccine groups used in Trial I and Trial II.
Group Dosage of protein
Trial Ia PAN-Lysate 75 µg soluble+ 25 µg encapsulated
Lysate (no PAN) 100 µg soluble
Mycopar® 100 µL
PBS 100 µL
Trial IIb PAN-Lysate 75 µg soluble+ 25 µg encapsulated
PAN-Cf 75 µg soluble+ 25 µg encapsulated




aLysate obtained from M. paratuberculosis K10.
bLysate obtained from M. paratuberculosis JTC-1285.
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cells were washed with PBS twice. Fixable Viability Dye efluor 780
(eBioscience, San Diego, CA) was diluted in PBS (1/10) and added to each
well except unstained control, incubated for 30min in dark at 2–8 °C and
CD16/Cd32 receptors were blocked with Fc block (BD Pharmingen, San
Diego, CA). Cell surfaces were stained with cocktail of BUV496 conjugated
anti-CD4 antibody, clone GK 1.5 (BD Pharmingen); BUV396 conjugated
anti-CD8, clone 53-6.7 (BD Pharmingen); BV711 conjugated anti-CD25,
clone PC61 (Biolegend) and incubated for 30min in dark at 4 °C. Cells were
washed with cold FACS buffer twice and resuspended in 200 μL of
Fixation/Permeabilization working solution (Foxp3 staining buffer set,
eBioscience, San Diego, CA). After 1 h incubation, cells were washed with
1X permeabilization buffer and stained intracellularly with APC conjugated
anti-IFN-γ, clone XMG1.2 (BD Pharmingen); PE conjugated anti-IL-2 (BD
Pharmingen); PEcy7 conjugated anti-TNFα, clone MP6-XT22 (eBioscience);
and Alexa Fluor 780 conjugated anti-Foxp3, clone FJK16s (eBioscience).
Cells were analyzed using BD FACSCalibur and data were analyzed using
FlowJo software (FlowJo, LLC, Ashland, OR). Results were expressed as the
increase in the percentage of the cells with positive staining relative to that
of an unstimulated sample stained with the same antibody.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (La Jolla, CA). Data
were analyzed using one-way ANOVA followed by Tukey’s multiple
comparison. Results with p < 0.05 or better were considered significant.
All research reported here was conducted in accordance with all relevant
guidelines and procedures, and that the work was approved by the
University of Wisconsin–Madison.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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